Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats

L. Uttl, T. Hložek, P. Mareš, T. Páleníček, H. Kubová

. 2021 ; 23 (1) : . [pub] 20211222

Language English Country Switzerland

Document type Journal Article

Grant support
LO1611 Ministry of Education Youth and Sports
RVO: 67985823 Ministry of Health
No. CZ.02.1.01/0.0/0.0/16_025/0007444 Ministry of Education Youth and Sports

In spite of use of cannabidiol (CBD), a non-psychoactive cannabinoid, in pediatric patients with epilepsy, preclinical studies on its effects in immature animals are very limited. In the present study we investigated anti-seizure activity of CBD (10 and 60 mg/kg administered intraperitoneally) in two models of chemically induced seizures in infantile (12-days old) rats. Seizures were induced either with pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA). In parallel, brain and plasma levels of CBD and possible motor adverse effects were assessed in the righting reflex and the bar holding tests. CBD was ineffective against NMDA-induced seizures, but in a dose 60 mg/kg abolished the tonic phase of PTZ-induced generalized seizures. Plasma and brain levels of CBD were determined up to 24 h after administration. Peak CBD levels in the brain (996 ± 128 and 5689 ± 150 ng/g after the 10- and 60-mg/kg doses, respectively) were reached 1-2 h after administration and were still detectable 24 h later (120 ± 12 and 904 ± 63 ng/g, respectively). None of the doses negatively affected motor performance within 1 h after administration, but CBD in both doses blocked improvement in the bar holding test with repeated exposure to this task. Taken together, anti-seizure activity of CBD in infantile animals is dose and model dependent, and at therapeutic doses CBD does not cause motor impairment. The potential risk of CBD for motor learning seen in repeated motor tests has to be further examined.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011653
003      
CZ-PrNML
005      
20220506130921.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms23010094 $2 doi
035    __
$a (PubMed)35008517
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Uttl, Libor $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Topolová 748, 250 67 Klecany, Czech Republic $u Laboratory of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic $1 https://orcid.org/0000000305721213
245    10
$a Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats / $c L. Uttl, T. Hložek, P. Mareš, T. Páleníček, H. Kubová
520    9_
$a In spite of use of cannabidiol (CBD), a non-psychoactive cannabinoid, in pediatric patients with epilepsy, preclinical studies on its effects in immature animals are very limited. In the present study we investigated anti-seizure activity of CBD (10 and 60 mg/kg administered intraperitoneally) in two models of chemically induced seizures in infantile (12-days old) rats. Seizures were induced either with pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA). In parallel, brain and plasma levels of CBD and possible motor adverse effects were assessed in the righting reflex and the bar holding tests. CBD was ineffective against NMDA-induced seizures, but in a dose 60 mg/kg abolished the tonic phase of PTZ-induced generalized seizures. Plasma and brain levels of CBD were determined up to 24 h after administration. Peak CBD levels in the brain (996 ± 128 and 5689 ± 150 ng/g after the 10- and 60-mg/kg doses, respectively) were reached 1-2 h after administration and were still detectable 24 h later (120 ± 12 and 904 ± 63 ng/g, respectively). None of the doses negatively affected motor performance within 1 h after administration, but CBD in both doses blocked improvement in the bar holding test with repeated exposure to this task. Taken together, anti-seizure activity of CBD in infantile animals is dose and model dependent, and at therapeutic doses CBD does not cause motor impairment. The potential risk of CBD for motor learning seen in repeated motor tests has to be further examined.
650    _2
$a zvířata $7 D000818
650    _2
$a antikonvulziva $x farmakologie $7 D000927
650    _2
$a mozek $x účinky léků $7 D001921
650    _2
$a kanabidiol $x farmakokinetika $x farmakologie $7 D002185
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a epilepsie $x farmakoterapie $7 D004827
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a N-methylaspartát $x farmakologie $7 D016202
650    _2
$a pentylentetrazol $x farmakologie $7 D010433
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a záchvaty $x farmakoterapie $7 D012640
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hložek, Tomáš $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic
700    1_
$a Mareš, Pavel $u Laboratory of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
700    1_
$a Páleníček, Tomáš $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Topolová 748, 250 67 Klecany, Czech Republic $u Department of Psychiatry and Medical Psychology 3FM CU and NIMH, 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 100 00 Prague, Czech Republic
700    1_
$a Kubová, Hana $u Laboratory of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 1 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35008517 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130913 $b ABA008
999    __
$a ok $b bmc $g 1789321 $s 1162851
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 1 $e 20211222 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a LO1611 $p Ministry of Education Youth and Sports
GRA    __
$a RVO: 67985823 $p Ministry of Health
GRA    __
$a No. CZ.02.1.01/0.0/0.0/16_025/0007444 $p Ministry of Education Youth and Sports
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...